Millennium Management LLC Cuts Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI)

Millennium Management LLC reduced its position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) by 17.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 80,538 shares of the company’s stock after selling 17,350 shares during the quarter. Millennium Management LLC owned about 0.26% of TriSalus Life Sciences worth $403,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Bank of America Corp DE raised its position in shares of TriSalus Life Sciences by 120,471.6% in the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company’s stock worth $894,000 after buying an additional 178,298 shares during the period. Northern Trust Corp raised its position in shares of TriSalus Life Sciences by 22.7% in the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock worth $161,000 after buying an additional 5,936 shares during the period. Renaissance Technologies LLC purchased a new position in TriSalus Life Sciences in the fourth quarter valued at about $67,000. Geode Capital Management LLC raised its position in TriSalus Life Sciences by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 204,137 shares of the company’s stock valued at $1,023,000 after purchasing an additional 3,710 shares during the period. Finally, Bridgeway Capital Management LLC raised its position in TriSalus Life Sciences by 333.3% in the fourth quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company’s stock valued at $326,000 after purchasing an additional 50,000 shares during the period. 2.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the company. Canaccord Genuity Group reissued a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research report on Friday, March 28th. Lake Street Capital assumed coverage on TriSalus Life Sciences in a research report on Thursday, February 13th. They issued a “buy” rating and a $10.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $10.75.

Insider Buying and Selling

In related news, insider Richard Marshak sold 6,597 shares of TriSalus Life Sciences stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $5.18, for a total value of $34,172.46. Following the completion of the transaction, the insider now directly owns 69,101 shares in the company, valued at approximately $357,943.18. This trade represents a 8.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders sold 16,125 shares of company stock worth $83,528. Corporate insiders own 27.50% of the company’s stock.

TriSalus Life Sciences Price Performance

Shares of TriSalus Life Sciences stock opened at $5.59 on Tuesday. The business has a 50-day moving average of $5.39 and a 200-day moving average of $5.14. The company has a market capitalization of $211.52 million, a PE ratio of -2.24 and a beta of 0.47. TriSalus Life Sciences, Inc. has a 1-year low of $3.50 and a 1-year high of $6.62.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The firm had revenue of $9.17 million during the quarter, compared to the consensus estimate of $9.04 million. During the same period in the previous year, the company earned ($0.60) EPS. On average, equities analysts expect that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current fiscal year.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.